Aakash Desai/LinkedIn
May 15, 2025, 05:24
Aakash Desai: Another ADC lands in lung cancer
Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Another ADC lands in lung cancer.
On May 14, 2025, the FDA granted accelerated approval to telisotuzumab vedotin (Emrelis) for adults with previously treated, advanced non-squamous NSCLC harboring high c-Met protein overexpression (≥50% 3+ IHC).
Approved alongside the VENTANA MET (SP44) RxDx Assay as the companion diagnostic.
Based on LUMINOSITY trial (N=84):
- ORR: 35%
- Median DOR: 7.2 months
- Notable AEs: peripheral neuropathy, fatigue, ↓ appetite, edema
- Dose: 1.9 mg/kg IV q2w
This adds another option for EGFR-wt, c-Met high NSCLC—especially where targeted options remain limited. The field of antibody-drug conjugates (ADCs) continues to grow rapidly. Read more.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 18, 2025, 13:40
May 18, 2025, 13:31
May 18, 2025, 12:54